Story perspectives

Merck Raises 2025 Earnings Outlook After Keytruda Surge

By Drooid · Oct 29, 2026 · How we work

Read the story

Story summary

Summary

Merck raised its adjusted earnings outlook to $2.77-$2.82 per share on Thursday.
The company narrowed its 2026 revenue guidance low end to $66.8 billion.
Merck recorded a one-time $400 million charge for a licensing deal with SciBrunch.
Keytruda sales reached $8.60 billion, a 6% year-over-year increase.
Winrevair sales jumped 94% to $694 million, beating analysts’ $645 million forecast.

1 of 1

Merck raised its adjusted earnings outlook to $2.77-$2.82 per share on Thursday.
The company narrowed its 2026 revenue guidance low end to $66.8 billion.
Merck recorded a one-time $400 million charge for a licensing deal with SciBrunch.
Keytruda sales reached $8.60 billion, a 6% year-over-year increase.
Winrevair sales jumped 94% to $694 million, beating analysts’ $645 million forecast.